Lead Sponsor

RenJi Hospital

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•Histological or cytological confirmed advanced, recurrent, of metastatic gastric adenocarcinoma or adenocarcinoma of esophagogastric junction;
•ECOG PS: 0-2;
•Adequate hepatic, renal, heart, and hematologic functions;
•At least one measurable lesion (according to RECIST1.1);
•Haven't received any systematic treatment for the cancer involved;
•Expected survival \> 12 weeks;
•Contraception until 6 months after the study termination;
•Signed informed consent.

•Her-2-positive gastric cancer, or exposed to any immune checkpoint inhibitor;
•Participated in another study;
•Immunodeficiency;
•Received allograft；
•Unmanageable hypertension, diabetes, or coronary disease;
•Have difficulty in taking medicine, or active bleeding;
•Pulmonary tuberculosis, or interstitial lung disease that needs steroid therapy;
•Infection of HIV, HBV, HCV, or other unmanageable infection;
•Other malignant tumor history;
•Allergic to the test drug;
•Other diseases which will affect the results of this study;
•Received resection of stomach;
•Taking anti-tumor traditional Chinese Medicine;
•Severe active bleeding.

Related studies

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more

NCT07504913 · Stomach Neoplasms, Validation Study

NCT06885697 · Mesothelioma, Neoplasms, and more

NCT07309185 · Stomach Neoplasms

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer